Compare FirstEnergy Corp. (FE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Gilead Sciences, Inc. — how do they compare? FirstEnergy Corp. trades at $49.01 (market cap $28.13B), while Gilead Sciences, Inc. trades at $135.44 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 5.8× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (3.82%). Which is the better fit depends on your goals.
| FE | GILD | |
|---|---|---|
Market Cap | $28.13B | $163.51B |
Sector | Utilities | Health |
52-Week High | $51.91 | $155.80 |
52-Week Low | $40.30 | $108.22 |
Enterprise Value | $56.14B | $178.05B |
Dividend Yield | 3.82% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy Corp. (FE) trades at $49.17, down 0.1% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue growth is steady at $15.09 billion for 2025. The company benefits from rising data center demand and a $36 billion investment plan, highlighted by recent news of grid upgrades and leadership appointments to drive operational performance.
Outlook is positive with a consensus price target of $52.00, offering ~6% upside. Key opportunities include infrastructure investments and data center growth, but risks involve high debt levels and regulatory pressures. Institutional sentiment is bullish with no sell ratings, though net cash flow remains negative, requiring careful monitoring of capital expenditures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
